Your browser is no longer supported. Please, upgrade your browser.
Sesen Bio, Inc.
Index- P/E- EPS (ttm)-0.90 Insider Own0.02% Shs Outstand169.39M Perf Week-1.88%
Market Cap747.51M Forward P/E96.98 EPS next Y0.04 Insider Trans0.00% Shs Float167.51M Perf Month44.29%
Income-119.30M PEG- EPS next Q-0.06 Inst Own23.50% Short Float4.76% Perf Quarter31.13%
Sales15.50M P/S48.23 EPS this Y83.90% Inst Trans44.23% Short Ratio1.32 Perf Half Y142.44%
Book/sh0.06 P/B69.50 EPS next Y108.50% ROA- Target Price7.00 Perf Year472.88%
Cash/sh0.61 P/C6.80 EPS next 5Y- ROE- 52W Range0.66 - 4.68 Perf YTD208.89%
Dividend- P/FCF- EPS past 5Y35.90% ROI244.80% 52W High-10.90% Beta0.83
Dividend %- Quick Ratio7.30 Sales past 5Y62.60% Gross Margin- 52W Low529.91% ATR0.28
Employees27 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)65.27 Volatility8.52% 7.87%
OptionableYes Debt/Eq0.00 EPS Q/Q-195.90% Profit Margin- Rel Volume1.08 Prev Close4.35
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume6.06M Price4.17
Recom1.30 SMA2010.38% SMA5036.34% SMA200101.15% Volume6,632,204 Change-4.14%
Jun-11-19Upgrade H.C. Wainwright Neutral → Buy $3
Jun-18-21 08:03AM  
Jun-15-21 06:08AM  
Jun-02-21 08:00AM  
Jun-01-21 08:00AM  
May-27-21 08:00AM  
May-25-21 10:38AM  
May-21-21 04:30PM  
May-10-21 07:30AM  
May-04-21 08:00AM  
May-03-21 08:00AM  
Apr-16-21 04:30PM  
Apr-08-21 08:55AM  
Apr-07-21 08:00AM  
Mar-22-21 08:01AM  
Mar-15-21 07:00AM  
Mar-08-21 08:00AM  
Mar-02-21 08:00AM  
Feb-16-21 12:40PM  
Feb-12-21 04:30PM  
Feb-11-21 09:13AM  
Feb-01-21 08:00AM  
Jan-25-21 11:37AM  
Jan-13-21 08:00AM  
Dec-31-20 08:55AM  
Dec-21-20 08:00AM  
Dec-18-20 08:00AM  
Dec-16-20 01:57PM  
Dec-09-20 08:45AM  
Dec-07-20 08:00AM  
Dec-02-20 10:58PM  
Dec-01-20 08:00AM  
Nov-16-20 03:52AM  
Nov-09-20 07:30AM  
Nov-02-20 08:00AM  
Oct-26-20 08:00AM  
Oct-19-20 08:00AM  
Sep-15-20 10:09AM  
Sep-08-20 07:00AM  
Sep-01-20 08:41AM  
Aug-10-20 07:30AM  
Aug-05-20 04:15PM  
Jul-31-20 07:30AM  
Jul-30-20 08:00AM  
Jun-12-20 04:04AM  
Jun-05-20 03:18PM  
May-26-20 07:00AM  
May-11-20 07:00AM  
May-07-20 04:41PM  
May-04-20 08:00AM  
Apr-07-20 05:20AM  
Mar-16-20 09:07AM  
Feb-25-20 04:30PM  
Feb-24-20 04:30PM  
Jan-31-20 08:00PM  
Jan-14-20 02:08PM  
Dec-30-19 11:17AM  
Dec-09-19 07:30AM  
Dec-05-19 07:14AM  
Dec-04-19 04:30PM  
Dec-02-19 10:53PM  
Nov-30-19 10:18AM  
Nov-12-19 07:00AM  
Nov-06-19 08:21AM  
Nov-05-19 04:48PM  
Oct-29-19 04:05PM  
Sep-23-19 12:32PM  
Aug-27-19 07:29AM  
Aug-26-19 04:05PM  
Aug-08-19 04:01PM  
Aug-05-19 07:30AM  
Jul-31-19 07:30AM  
Jul-25-19 12:33PM  
Jul-17-19 04:10PM  
Jun-25-19 08:37AM  
Jun-22-19 02:35PM  
Jun-21-19 08:42AM  
Jun-19-19 08:00AM  
Jun-18-19 04:17PM  
Jun-10-19 07:00AM  
Jun-07-19 07:00AM  
May-21-19 07:00AM  
May-20-19 11:26AM  
May-13-19 07:00AM  
May-01-19 07:45AM  
Apr-29-19 07:30AM  
Mar-28-19 09:45AM  
Mar-27-19 08:00AM  
Mar-09-19 10:09PM  
Mar-07-19 12:56PM  
Mar-04-19 07:30AM  
Feb-25-19 04:20PM  
Jan-22-19 09:30AM  
Jan-18-19 11:36AM  
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.